salmeterol/fluticazona genetic 25 micrograme/250 micrograme/doza
genetic s.p.a. - italia - salmeterolum+fluticasonum - susp. de inhalat presurizata - 25micrograme/250micrograme/doza - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
salmeterol/fluticazona genetic 25 micrograme/50 micrograme/doza
genetic s.p.a. - italia - salmeterolum+fluticasonum - susp. de inhalat presurizata - 25micrograme/50micrograme/doza - adrenergice inhalante adrenergice si alte med. pt. trat. bolilor obstructive c.r
ipravent inhaler solutie de inhalat presurizata 20 mcg/doza
cipla uk limited - ipratropii bromidum - solutie de inhalat presurizata - 20 mcg/doza
beclazone-eco solutie de inhalat presurizata 100 mcg/doza
teva pharmaceutical industries ltd - beclometasoni dipropionas - solutie de inhalat presurizata - 100 mcg/doza
beclazone-eco solutie de inhalat presurizata 250 mcg/doza
teva pharmaceutical industries ltd - beclometasoni dipropionas - solutie de inhalat presurizata - 250 mcg/doza
ipravent inhaler 20 micrograme/doza
cipla (uk) limited - ipratropii bromidum - sol. de inhal. presurizata - 20micrograme/doza - alte med.pt.trat.bolilor obstructive ale c.r, inhalatorii anticolinergice
budiair 200 mcg
chiesi farmaceutici s.p.a. - budesonidum - sol. de inhalat presurizata - 200 mcg/doza - alte med. pt.trat.bolilor obstructive ale c.r, inhalatorii glucocorticoizi
budiair 200 mcg jet
chiesi farmaceutici s.p.a. - budesonidum - sol. de inhalat presurizata - 200mcg/doza - alte med. pt.trat.bolilor obstructive ale c.r, inhalatorii glucocorticoizi
senstend
plethora pharma solutions limited - lidocaina, prilocaina - ejacularea prematura - anestezice - senstend este indicat pentru tratamentul primar ejaculare precoce la bărbați adulți.
trixeo aerosphere
astrazeneca ab - formoterol fumarate dihydrate, glycopyrronium bromide, budesonide - boala pulmonară, obstructivă cronică - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - trixeo aerosphere is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long acting beta2 agonist or combination of a long-acting beta2 agonist and a long acting muscarinic antagonist.